Financial Data and Key Metrics Changes - For the third quarter of fiscal 2026, revenue increased by 10.2% to $4 million from $3.6 million in the prior year quarter [10] - Gross profit for the quarter totaled $3.2 million, up 17.6% from $2.8 million for the prior year period, with a gross profit percentage improvement to 81.5% from 76.4% [11] - EBITDA for the quarter was $280,000, corresponding to $0.01 on a per-share basis, marking the third consecutive quarter of positive EBITDA [14] Business Line Data and Key Metrics Changes - Recurring revenue reflects strong market adoption of the primary subscription model, driven by the popularity of FDA-cleared cardiac monitor devices, particularly the next-generation Biotres Pro [9] - Technology fees accounted for 91.2% of the quarter's total revenue, indicating strong customer retention and quality of support services [11] - Sales of BioCore Pro, the next-generation cardiac monitoring device, continued to expand, contributing to improved utilization and accelerating the path towards breakeven [7] Market Data and Key Metrics Changes - The digital health app user base grew from 4,500 to over 44,000 in two years, with an expanding network of over 2,500 providers supporting 400,000 patients annually [10] - The focus on atrial fibrillation as a primary contributor to strokes remains significant, with early intervention opportunities improving patient outcomes and potentially delivering healthcare cost savings [10] Company Strategy and Development Direction - The company is focused on transitioning from reactive care to proactive management in chronic care markets, particularly in cardiovascular disease [3][4] - Biotricity aims to expand its geographic footprint and is pursuing regulatory approvals internationally while maintaining a primary focus on U.S. market expansion [5][12] - The strategic initiatives and technological advancements are designed to position Biotricity for sustained growth and profitability in 2026 [8][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth and the expectation of turning net income positive in the current year [18] - The company is excited about the prospects for 2026, anticipating sustained growth in the top line and improvements in operational efficiencies [16][18] Other Important Information - Operating expenses for the third quarter were $2.8 million, a decrease of 4.2% compared to the same period last year [12] - The net loss attributable to common stockholders for the quarter was $1.1 million, an improvement from $1.3 million in the prior year period [15] Q&A Session Summary - There were no questions during the Q&A session, and the conference concluded with management expressing excitement about future prospects [17][19]

Core Insights - Biotricity Inc. continues to demonstrate strong financial performance with positive EBITDA and ongoing revenue growth [1] - The company is set to host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11, 2026, at 4:30 PM ET [2] - Biotricity is focused on transforming the healthcare industry through innovative remote monitoring and diagnostic solutions [1][3] Financial Performance - The company has achieved a positive EBITDA, indicating improved operational efficiency and margin strength [1] - Continued growth in financial performance is highlighted, although specific revenue figures are not disclosed [1] Business Update Call - The upcoming call will feature remarks from Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, followed by a Q&A session for investors [1][2] - Investors can access the call via a toll-free number or through a webcast, with a replay available approximately three hours after the live event [2][3] Company Overview - Biotricity is dedicated to bridging gaps in remote monitoring and chronic care management, providing trusted solutions for preventive and personal care [3] - The company develops comprehensive remote health monitoring solutions for both medical and consumer markets [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 3845 (Primary Standard Industrial Classification Code Number) 30-0983531 (I.R.S. Employer Identification Number) 203 Redwood Shores Parkway, Suite 600 Redwood City, CA 94065 (904) 496-0027 (Address, including zip code, and telephone n ...

As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOTRICITY INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Nevada 3845 30-0983531 203 Redwood Shores Parkwa ...